Education
About Us
Working with TipRanks
Follow Us
Microba Life Sciences Limited (AU:MAP)
ASX:MAP
MAP Stock Chart & Stats
AU$0.08
>-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.23
Previous CloseN/A
Volume476.46K
Average Volume (3M)469.77K
Market Cap
AU$48.72M
Enterprise ValueAU$33.16M
Total Cash (Recent Filing)AU$11.27M
Total Debt (Recent Filing)AU$3.31M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.21Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.83M
Bulls Say, Bears Say
Bulls Say
Low Leverage (debt-to-equity 0.10)Very low debt-to-equity (0.10) gives durable financial flexibility: lower interest burden and greater ability to fund R&D or absorb revenue volatility without immediate refinancing. This structural strength supports long-term product development and partnership execution.
Positive Free Cash Flow GrowthFree cash flow growing (4.68%) and exceeding net income indicates the business can generate cash beyond accounting losses. Over months this supports operational runway, selective reinvestment in sequencing capacity and analytics, and reduces reliance on equity raises if sustained.
Platform-based, Diversified Revenue StreamsA platform combining sequencing, bioinformatics and test services creates multiple durable revenue channels (direct tests, B2B services, collaborations). This structural diversity helps capture recurring test demand, margin-enhancing service contracts, and R&D partnerships over the medium term.
Bears Say
Declining RevenueA steep revenue decline (-24.28%) is a durable risk: shrinking top line reduces scale benefits, limits R&D and marketing investment, and increases pressure on fixed-cost absorption. Continued contraction would hinder path to sustainable profitability and commercial momentum.
Persistent Negative ProfitabilityNegative EBIT/EBITDA and net profit margins signal structural unprofitability: ongoing losses erode retained earnings and return on equity, necessitating external funding or structural cost reductions to reach sustainable margins and support longer-term commercial expansion.
Negative Operating Cash FlowPersistent negative operating cash flow, despite FCF growth, indicates operational cash generation issues (working capital, timing, or core margin shortfalls). Over months this raises liquidity risk and the likelihood of financings that could dilute shareholders or constrain strategic initiatives.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.07 and its highest was AU$0.23 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$48.72M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Sep 02, 2026 which is in 167 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.008.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 608,963,000 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.018 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.21 (162.50% Upside)
AU$0.21 (162.50% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.76%
12-Months-Change
Fundamentals
Return on Equity
-63.04%
Trailing 12-Months
Asset Growth
-14.63%
Trailing 12-Months
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.21
▲(162.50% Upside)
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---